ArticleGenes2026
Genomic Markers of Heavy Alcohol Consumption Outperform Self-Report and Other Common Predictors of Mortality in Two Middle-Aged Samples of Black Americans.
Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectivesHeavy alcohol consumption (HAC) may contribute to elevated mortality risk in middle age, but its contribution to mortality in middle age among Black Americans is poorly characterized, suggesting the potential for genomic variables to improve prediction. We examined whether a DNA methylation-based measure of HAC (HAC/ATS) increased prediction of mortality beyond Chronic Illnesses and other controls and compared its predictive abilities to that of self-reported HAC.
methodsSAMPLE: Two longitudinal samples were examined to test hypotheses. First, we examined the Family and Community Health Study (FACHS) sample, comprising 360 individuals who were 95.8% female, with a mean age of 47.12 at the time of their blood draw, and followed for 17 years. Second, we examined the Promoting Strong African American Families (ProSAAF) sample comprising 336 individuals who were 54.8% female, with a mean age 44.64 at the time of their initial blood draw, and followed for 5 or more years. To overcome potential biases arising from small sample sizes we used Firth's penalized likelihood logistic regression analyses to predict mortality in both samples.
resultsIn both samples, the DNA-methylation-based indicator of HAC (HAC/ATS) significantly contributed to the prediction of mortality beyond the significant contribution of age, Number of Chronic Illnesses, and other control variables. This was in contrast to the non-significant contribution of self-reported HAC. In both samples, high blood pressure was also a significant predictor of mortality, albeit not as powerful a predictor as DNA-methylation-based indicator of HAC.
conclusionsA DNA-methylation-based indicator of HAC (HAC/ATS) made a substantial contribution to mortality risk in two longitudinal samples of middle-aged African Americans. Significant contributions of Chronic Illness suggested the value of future exploration of genomic indicators of HAC in combination with chronic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.